Interested in working on RNA-biology in human disease? We can offer a PhD student position in a great team. Looking into RNA-modifications as a driver of polycystic kidney disease together with @landthalerm.bsky.social www.jobvector.de/job/phd-stud...

Impact on Cost and Expert Time of Data-Efficient Deep Learning for Medical Image Segmentation https://doi.org/10.1148/ryai.250200 @muellerrom.bsky.social #Segmentation #AI #MachineLearning

An expert-guided annotation loop reduced expert annotation time and enabled estimated cost savings while producing high-quality reference standard CT and MRI segmentations https://doi.org/10.1148/ryai.250200 @muellerrom.bsky.social #MRI #CT #ML

🧵 (4/4) 🌍 Please check the map available on the study website to identify the nearest participating centre. If you need any support or guidance, we would be very happy to support you or to connect you with your local patient association. @uniklinikkoeln.bsky.social @muellerrom.bsky.social

🧵 🧪 STOP-PKD study | New recruitment sites Research on ADPKD continues to move forward: stop-pkd.de/en

We’re excited to share our latest publication in npj Aging on the molecular effects of short-term calorie restriction before living kidney donation. Using proteomics, lipidomics, and cytokine profiling, we found that just 7 days of 50% calorie restriction induced molecular signatures linked to: 🧵

The fact that primary hyperoxaluria is the first kidney disease for which an RNA therapeutic has become available is a milestone for the field. How does this change the treatment landscape? 🧵

🧵 🧬 ADPKD research needs your voice The future of ADPKD research is evolving — and patient perspectives are essential to guide this change.

🔬🩺 From bench to bedside Professor @olivercornely.bsky.social und Professor @muellerrom.bsky.social explain in the new #Unimagazin how Basic Research leads to medical Progress. Read more ▶️ uni.koeln/2VKJM #uniköln #unicologne #transationalresearch @cecad.bsky.social

🔬🩺 Aus dem Labor ans Krankenbett Wie aus Grundlagenforschung medizinischer Fortschritt wird erklären Professor @olivercornely.bsky.social und Professor @muellerrom.bsky.social im aktuellen #Unimagazin. Zum Artikel ▶️ uni.koeln/LHSE3 #uniköln #unicologne #transationalresearch @cecad.bsky.social

🧵 🧪 STOP-PKD study | Expanding recruitment across Europe: stop-pkd.de/en The STOP-PKD study continues to expand, marking an important step forward for ADPKD research in Europe.

I usually think twice before posting preprints. But this time it’s different. MEDA-PKD is the essence of our work over more than a decade — and, to me, one of the most meaningful contributions I’ve been able to make to biomedical research. 🧵

New publication on hereditary kidney tumors. Our questionnaire-based screening approach (referenced in the German giudeline) has now been validated. A step toward better identification of patients who may benefit from genetic evaluation and personalized care. 📖 academic.oup.com/ckj/advance-...

ADPKD comes with increased risk of aneurysms. This manifestation comes concern, for both patients and MDs. Risk assessment? Screening? Treatment decisions? This ERA Genes&Kidney commentary provides fin-depth guidance based on the @kdigo.org ADPKD guideline. academic.oup.com/ndt/article/...

🧵 🧬 Help shape the future of ADPKD research Are you living with ADPKD? Your perspective matters. PKD International is part of the ARTICYST Project, a European initiative bringing together research centres and the patient community to improve the future of ADPKD research.

🧵We are pleased to announce that the UMCG - Universitair Medisch Centrum Groningen in the Netherlands is now officially accredited as a trial site for the STOP-PKD Study.

🧵🧪 Important recruitment update on the STOP-PKD study (1/6) We are very pleased to share a significant update on the #STOP-PKD study, an important European research initiative for people living with #ADPKD.

🧵 1/4 Living with #ADPKD? Take the survey and use your voice to shape the future of ADPKD research. 📣 survey.uni-koeln.de/index.php/31... 🪡 Read this thread 👇 #PKD #PatientVoice #OpenScience #RareDisease #KidneyHealth #HorizonEurope #European #Research

🧵🧪 Important recruitment update on the STOP-PKD study (1/6) We are very pleased to share a significant update on the #STOP-PKD study, an important European research initiative for people living with #ADPKD.

My first rare disease day at University Hospital Düsseldorf. Great to see this is an active topic on site. Looking forward to setting up the Center for Rare and Genetic Kidney Diseases and continuing the efforts to improve patient care and research in this area. @hhu.de

🚀 STOP-PKD-News! Das zweite Prüfzentrum in Mainz ist nun offiziell freigegeben. Weitere folgen (DE, NL, ES, AT). Kann SGLT2-Inhibition das Fortschreiten von Zystennieren positiv beeinflussen? Infos und Kontakte: stop-pkd.de #STOPPKD #ADPKD @pkdinternational.bsky.social @pkdgermany.bsky.social

Looking forward to continuing the collaboration with @pkdinternational.bsky.social in this new position.

👩‍🔬 Today is International Day of Women and Girls in Science! Meet Malvika Ramani, PhD student in the group of @muellerrom.bsky.social at the @unicologne.bsky.social

The important pediatric perspective on CKDx. Moving nephrology towards precision medicine is an effort spanning all age groups. Improving precision diagnosis in unexplained CKD url: academic.oup.com/ckj/article/...

SGLT-2 Inhibition in ADPKD? DAPA-PKD & STOP-PKD - Prof. Emilie Cornec Le Gall & Prof. Roman-Ulrich Müller youtu.be/9e-UFBnIyDI?... @ecorneclegall.bsky.social @muellerrom.bsky.social @kronbichlerlab.bsky.social @sarahelena.bsky.social @gunnarheine.bsky.social @marcussaemann.bsky.social

Transition of patients with hereditary nephropathies from pediatric to adult care url: academic.oup.com/ndt/article-... Transition…such an important topic for improving patient care…but still underrepresented in care pathways.

Tonight it's all about ADPKD! KDIGO Guidelines / ERA Genes & Kidney Working Group - Prof. Roser Torra, Prof. Roman-Ulrich Müller youtu.be/qjnYDsYbx0Q?... @rosertorra.bsky.social @muellerrom.bsky.social @dguerrot.bsky.social @gunnarheine.bsky.social @kronbichlerlab.bsky.social

📹 Interested in a PhD position in aging research starting in 2026? Then watch our new short video for some tips from our wonderful PhD students and faculty. Don't miss the deadline: November 3, 2025. Apply now and start your journey with us!

KDIGO 2025 ADPKD Guideline: A commentary on diagnosis and management of hepatopancreatic manifestations by the ERA Working Group Genes & Kidney by Drs. @muellerrom.bsky.social , @joostphdrenth.bsky.social, et al. academic.oup.com/ndt/article/...

The KDIGO ADPKD Guideline is a milestone for the field. Building upon this work, experts assembled by the ERA Working Group Genes&Kidney now provide additional practical guidance for polycystic liver disease in #ADPKD. academic.oup.com/ndt/article/... @ecorneclegall.bsky.social

CKDx: Simplicity matters, implementation is key url: academic.oup.com/ndt/article/... At this stage, it is all about widespread adoption of a simple concept: we do not always know the diagnosis in kidney disease. And reporting diagnostic steps in a simple manner enables us to go the next step.

Apply now for a fully funded #PhD position at the Cologne Graduate School of Ageing Research and become part of our vibrant #AgingResearch commmuny. 🗓️ Deadline: November 3, 2025. ℹ️ More info: www.ageing-grad-school.de 📣 Spread the news!

Obtaining a thorough family history is so important in kidney disease....but often more difficult than expected in clinical practice... 10 tips on how to take a proper family history in CKD patient care url: academic.oup.com/ckj/article/...

Happy to share the nice video @unicologne.bsky.social has produced on our recent publication identifying novel protein biomarkers for #ADPKD. www.youtube.com/watch?v=FDGN... rdcu.be/ezvN4 @cecad.bsky.social @uniklinikkoeln.bsky.social

What happens when #mitochondria fail in high-energy tissues? Cells adjust their metabolism and alter the mechanics of the nucleus! Read more on the discovery by Dr. Harshita Kaul from the Trifunovic Lab in Nature Metabolism. ➡️ uni.koeln/QZURH #CellStress #NatureMetabolism @unicologne.bsky.social

Mithilfe von #Massenspektrometrie ist es einem Team um @muellerrom.bsky.social ‪vom @cecad.bsky.social an der @unicologne.bsky.social ‪und der @uniklinikkoeln.bsky.social ‪ gelungen, den Verlauf von Erkrankungen der #Nieren anhand einer Blutprobe deutlich genauer vorherzusagen als bisher möglich.

KDIGO ADPKD Guideline: A Milestone in Genetic Kidney Diseases Why is a global guideline for ADPKD so important? Prof. Roman Müller explains how the new KDIGO guideline marks a crucial step forward in harmonizing care for patients with #ADPKD) worldwide 👇

Great thanks to Jörg Bernards-Stiftung and @dfg.de (Excellence Strategy @cecad.bsky.social) for supporting this work and to all patients participating.

Interested in a postdoctoral fellowship on polycystic kidney disease? Linking molecular data with outcome? Please get in touch. euraxess.ec.europa.eu/jobs/hosting...

1/ 🧬 Exciting news! Our group just published a paper in Nature Communications on using serum proteomics to predict disease progression in #ADPKD (Autosomal Dominant Polycystic Kidney Disease) 🔬 — enhancing risk stratification beyond currently available models 🎯 rdcu.be/exbNq

📺 Patient-scientist collaboration – key to investigator-initiated trials: SGLT2i and beyond. In this video interview, Prof. @muellerrom.bsky.social highlights the power of working together: scientists, patients, and advocacy groups united to tackle the big questions in #PKD #PKDInternational

Samantha Filipow did a great job in defending her thesis on the role of a lncRNA in podocyte disease! Congratulations Samantha! It's been a pleasure working with you!

@oscarsproject.bsky.social making open science possible in Europe. Now also for genetic kidney disease

1/ 🚨 Big news from our Genes&Kidney Working Group at the European Renal Association (ERA)! We just released a consensus statement in Nephrology Dialysis Transplantation aiming to bring us closer to precision medicine in CKD. 🧬🩺 🧵 THREAD 👇

Chronic Kidney Disease of unexplained cause (CKDx): a consensus statement by the Genes & Kidney Working Group of the ERA doi.org/10.1093/ndt/...

🚀 Big news for kidney research! CRC/TRR 422 ‘PodoSigN’ has been funded to explore podocyte signaling networks. Proud to see two of our CRC 1678 Group Leaders @muellerrom.bsky.social and @inahuppertz.bsky.social involved in this groundbreaking work! #KidneyResearch #PodoSigN #DFGFunding

Finding the correct diagnosis is so important in kidney disease to allow for targeted treatment and avoid harm. And it’s equally important to openly address if the cause is not known. This is: CKD of unexplained cause (CKDx)

Great News!! Looking forward to working on RNA-binding metabolic enzymes in podocyte health with @inahuppertz.bsky.social @cecad.bsky.social @mpiage.bsky.social